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ABSTRACT
Objectives: The Commonwealth of Massachusetts increased
the copayment for prescription drugs by $1.50 for Medicaid
(MassHealth) beneﬁciaries in 2003. We sought to determine
the likely health outcomes and cost shifts attributable to this
copayment increase using the example of inhaled corticoster-
oids (ICS) use among adult asthmatic Medicaid beneﬁciaries.
Method: We compared the predicted costs and health
outcomes projected over a 1-year time horizon with and
without the increase in copayment from the perspective of
MassHealth, providers, pharmacies, and MassHealth beneﬁ-
ciaries by employing decision analysis simulation model.
Results: In a target population of 17,500 adult asthmatics,
increased copayments from 50¢ to $2.00 would result in an
additional 646 acute events per year, caused by increased
drug nonadherence. Annual combined net savings for the
state and federal governments would be $2.10 million. Pro-
jected MassHealth savings are attributable to both decreased
drug utilization and lower pharmacy reimbursement rates;
these more than offset the additional costs of more frequent
acute exacerbations. Pharmacies would lose $1.98 million in
net revenues, MassHealth beneﬁciaries would pay an addi-
tional $0.28 million, and providers would receive additional
$0.16 million.
Conclusion: Over its ﬁrst year of implementation, increase in
the prescription drug copayment is expected to produce more
frequent acute exacerbations among asthmatic MassHealth
beneﬁciaries who use ICS and to shift the ﬁnancial burden
from government to other stakeholders.
Keywords: asthma, copayment, medicaid, prescription
drug.
Introduction
The prescription drug beneﬁt is one of the fastest
growing components of Medicaid spending and one of
the program’s most widely utilized services [1]. Since
1998, pharmacy expenditures have risen almost twice
as fast as any other medical services [2]. Decreased
tax revenue, coupled with a double-digit increase in
health-care spending, have brought Medicaid pro-
grams under intense pressure to control cost [1,2].
As one response to the trend toward increase
cost sharing, the Massachusetts Medicaid program
(MassHealth) increased the prescription drug copay-
ment from 50¢ to $2.00 for MassHealth beneﬁciaries
in January 2003 [3]. Although many state Medicaid
programs use copayments to rein in unnecessary drug
utilization [4–6], the clinical and ﬁnancial impact of
such initiatives is not clear. Drug copayments may
cause patients to reduce essential drug utilization
[4,5,7–10], which in turn can lead to increased health
problems, and ultimately, greater acute-care outlays
[7,11]. Because poor and chronically ill beneﬁciaries
spend a higher share of their incomes on medical
expenses compared with healthy and higher-income
individuals [12], the burden of cost sharing falls dis-
proportionately on low-income patients with poor
health [4,5,13].
We used a decision-analytic approach to determine
the net economic and health outcomes associated with
an increase in prescription drug copayment in a low-
income population with a chronic disease. Using
the speciﬁc example of inhaled corticosteroid (ICS)
therapy among adult asthmatic MassHealth beneﬁcia-
ries, we explored how total costs and savings might be
allocated among different stakeholders (MassHealth,
providers, pharmacies, and MassHealth beneﬁciaries).
Asthma was chosen as the example, in part, because it
represents a condition that affects a broad cross section
of American society while focusing on vulnerable and
underserved populations.
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Methods
Overview
We modiﬁed a previously developed decision-analytic
model of asthma therapy to estimate clinical outcomes
and costs among adult asthmatic MassHealth beneﬁ-
ciaries receiving ICS therapy [14–17]. To predict the
induced costs attributable to an increase in copayment
for prescription drugs, we estimated expected out-
comes under two scenarios: “prepolicy” and “post-
policy.” For the prepolicy scenario, we estimated
1-year asthma-related outcomes for a hypothetical
population of asthmatic MassHealth beneﬁciaries all
treated with ICS therapy. For the postpolicy scenario,
we assumed that a proportion of that population
would be discouraged from ﬁlling their prescriptions
because of the copayment increase; we then separately
estimated 1-year asthma-related outcomes for the
treated and untreated populations.
Estimating Price Sensitivity of Demand for
Prescription Drugs
We assumed a 10% decrease in drug utilization attrib-
utable to the MassHealth copayment increase, based
on a critical review of the literature. Soumerai and
colleagues conclude that introducing copayments as
low as one dollar per prescription among Medicaid
beneﬁciaries produces 5% to 10% declines in overall
drug utilization [5]. In a study across all states, Stuart
and Zacker estimated that Medicaid prescription drug
copayments (ranging from 50¢ to $3.00) reduce
annual drug utilization by 15.5% [13]. Similarly, Lurk
et al. observed a 16.7% decrease in drug utilization in
an indigent population with a prescription copayment
increase of $2.50 (generic) and $5.00 (brand) in 2002
[18]. Nelson et al. found that the introduction of a 50¢
copayment in 1977 among South Carolina Medicaid
beneﬁciaries resulted in a 1-year decrease in drug uti-
lization of 11% [19]. Adjusting for inﬂation, this
ﬁnding is consistent with an approximate 10%
decrease in prescription reﬁll rates for a $1.50 copay-
ment increase in 2003. It is also comparable to ﬁndings
in a Canadian study on the indigent population [7].
We assumed that the 10% reduction applied spe-
ciﬁcally to ICS utilization. This assumption is consis-
tent with a previous study [9], which observed a
statistically signiﬁcant decrease in ICS utilization
among low-income Canadians after the implementa-
tion of prescription drug cost sharing. We explored
values ranging from 5% to 20% in sensitivity analyses.
Health Outcomes
We deﬁned our target population as adult MassHealth
beneﬁciaries with persistent asthma using ICS therapy.
We estimated the size of the target population at
17,500 based on the total number of adult MassHealth
beneﬁciaries (509,900) [20], the prevalence of persis-
tent asthma among adult Medicaid beneﬁciaries
(7.89% [21–23]; range from 3.37% [24] to 9.3%
[25]), and the fraction of daily ICS users among adult
Medicaid beneﬁciaries with persistent asthma (43.5%)
[26]. For our analysis, we modiﬁed the Asthma Policy
Model, a published, computer simulation of asthma’s
natural history and the health-economic outcomes of
patient care. Details of this model are described
elsewhere [14–17]. Brieﬂy, this is a Markov,
state-transition model [27] that characterizes the
progression of disease as a sequence of transitions
through a deﬁned set of health states, which are chosen
to be descriptive of current status, relevant history,
quality of life, and resource utilization. Each month
the model speciﬁes monthly risks of urgent-care visits,
emergency department (ED) visits, hospitalizations,
and mortality as a function of asthma severity, patient
age, and history of prior hospitalizations (none, once,
more than once). Disease severity is deﬁned by lung
function impairment as measured by the forced expi-
ratory volume in one second as a percent of predicted
normal (FEV1% predicted) [28], where a mean value
of 50 is assigned to patients with severe asthma, 70 to
moderate, and 90 to mild [16]. The impact of ICS
therapy is mediated entirely through lung function
[16]. Lung function, in turn, determines the risk of
urgent-care visits, ED visits, and hospitalizations. We
estimated that ICS therapy increased FEV1% predicted
by 7.6% for mild, 11.6% for moderate, and 17% for
severe asthmatic patients, which would in turn reduce
acute events, namely hospitalizations, ED visits, and
urgent-care visits [16]. The Asthma Policy Model pre-
dicts that lower ICS adherence will reduce FEV1%
predicted and thereby result in greater acute events.
Model Calibration: Utilization among Medicaid versus
Non-Medicaid Patients
The risk functions that predict acute events in the
Asthma Policy Model were estimated from data
obtained from a general asthmatic population. We esti-
mated new model parameters by calibrating model
outcomes to match those from a previous study of
Medicaid beneﬁciaries, using estimates of the distribu-
tion of disease severity from Medicaid populations.
Speciﬁcally, Piecoro and colleagues performed a cross-
sectional, retrospective analysis of Kentucky Medicaid
population to estimate utilization of asthma-related
health-care services [24]. They showed an age-adjusted
annual hospitalization rate of 74 per 1000 and ED
visits of 253 per 1000 adult asthmatic Medicaid ben-
eﬁciaries, whereas our model projected 37 hospitaliza-
tions and 102 ED visits per 1000 adult asthmatic
patients. Other studies estimated that among urban
residents, many of whom are Medicaid eligible,
asthma-related hospitalizations ranged from 41 to 68
per 10,000 residents [29,30], which is higher than
what is reported in a general asthmatic population
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(19.5 per 10,000 population [31]). Therefore, we cali-
brated our model to reﬂect the higher acute-care utili-
zation rates observed in Medicaid populations, where
ﬁnal calibration targets were 64 hospitalizations and
195 ED visits per 1000 adult asthmatic Medicaid
patients. We also conducted one-way sensitivity analy-
ses to investigate the degree to which variation in acute
event rates altered our results. Key model inputs are
shown in Table 1.
Costs
Monthly chronic and acute asthma care costs for
MassHealth beneﬁciaries were estimated based on pre-
viously published values [16,32–34] updated to 2003
US dollars using the Consumer Price Index (Table 1)
[35].MassHealth’s payment to providerswas estimated
based on payment-to-cost ratios from a publicly avail-
able ﬁnancial report [36]. MassHealth’s payment-to-
cost ratio for inpatient service was estimated to be 0.81
[36]. For outpatient service, the ratio was 0.58 [36]. We
categorized chronic care, urgent-care visits, and ED
visits as outpatient services and categorized hospitaliza-
tion as an inpatient service. The federal government
matched 53% of Medicaid spending in Massachusetts
[37], with the remainder paid by the state government.
We assumed that patients with mild/moderate
asthma who adhered to their drug regimen would take
400 mg of ICS per day, whereas patients with severe
asthma would take 1000 mg of ICS per day [28,38].
Based on these assumptions and the published average
wholesale price (AWP) per container [39], the monthly
AWP for mild/moderate asthma was $67.45 and for
patients with severe asthma was $168.63. Pharmacies
were reimbursed from MassHealth according to the
following formula [3]: 0.85 ¥ AWP ¥ 1.06 + $3.50
(dispensing fee) - copayment. Therefore, for mild/
moderate patients, MassHealth would pay $63.77 per
prescription under the prepolicy scenario and $62.27
per prescription under the postpolicy scenario. For
patients with severe disease, the pre- and postpolicy
MassHealth payments would be $154.93 and $153.43
per prescription, respectively.
We assumed that pharmacies collect all copayments
from MassHealth beneﬁciaries. We also assumed that
the reimbursement from MassHealth changed only
for pharmaceutical costs after the copayment was
increased and that reimbursement to providers
remained unchanged. To simplify our analysis, we
assumed that all MassHealth beneﬁciaries are enrolled
under the fee-for-service plans.
Table 1 Model inputs for adult asthmatic MassHealth population
Variable Base-case value
Range for sensitivity
analysis Source
Severity distribution (%) [21–23,44]
Mild persistent 35 27–47
Moderate 32 27–47
Severe 33 29–34
Rate of urgent-care visits (no. of events per
1000 person-months) among non-ICS users
[14–17,45,46]
Mild persistent 575 0.5–2 ¥ base case
Moderate 1042 0.5–2 ¥ base case
Severe 1464 0.5–2 ¥ base case
Rate of ED visits (no. of events per 1000
person-months) among non-ICS users (range)*
[14–17,45,46]
Mild persistent 105 (54–269) 0.5–2 ¥ base case
Moderate 264 (150–475) 0.5–2 ¥ base case
Severe 526 (352–543) 0.5–2 ¥ base case
Rate of hospitalization (no. of events per 1000
person-months) among non-ICS users (range)*
[14–17,45,46]
Mild persistent 25 (13–48) 0.5–2 ¥ base case
Moderate 76 (43–96) 0.5–2 ¥ base case
Severe 207 (138–228) 0.5–2 ¥ base case
MassHealth’s reimbursement to providers:
chronic care, per member per month ($)
[16,35,36]
Mild persistent 24.94 0.5–2 ¥ base case
Moderate 37.32 0.5–2 ¥ base case
Severe 43.21 0.5–2 ¥ base case
MassHealth’s reimbursement to providers:
acute care, per visit ($)
[16,32–36]
Urgent-care visit 41.25 0.5–3 ¥ base case
ED visit 158.44 0.5–3 ¥ base case
Hospitalization 2928.69 0.5–3 ¥ base case
ICS efﬁcacy (percent increase in FEV1% predicted) [16]
Mild persistent 8 0–22
Moderate 11 0–22
Severe 17 0–22
*Rates vary by age and history of hospitalizations.
ED, emergency department; ICS, inhaled corticosteroids.
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Results
Health Outcomes
Table 2 shows the expected health outcomes predicted
by our model for adult asthmatic MassHealth
(n = 17,500) beneﬁciaries over a 1-year time horizon,
under both the pre- and postpolicy scenarios. For the
prepolicy scenario, we predict MassHealth beneﬁcia-
ries would experience 13,185 urgent-care visits, 3871
ED visits, and 1340 hospitalizations. For the post-
policy scenario, a 10% drop in prescription reﬁlls
would result in an additional 646 acute events over a
1-year period: 469 urgent-care visits, 133 ED visits,
and 44 hospitalizations (Table 2).
Impact on Payer (MassHealth)
Table 3 shows the expected MassHealth (federal and
state government) outlays predicted by our model for
adult asthmatic beneﬁciaries over a 1-year time
horizon, under both the pre- and postpolicy scenarios.
These amounts represent the sum of payments to both
pharmacies and providers. For the prepolicy scenario,
we predict that federal and state government expendi-
tures would be $31.8 million over a 1-year period. For
the postpolicy scenario (with 10% decrease in pre-
scription reﬁlls), we predict that MassHealth payments
would decrease to $29.7 million, a savings of $2.1
million. The projected payment to providers would
increase by $0.16 million under the postpolicy, because
of the increased acute-care utilization caused by
increased drug nonadherence. Nevertheless, the
reduced payments to pharmacies ($2.26 million)
would more than offset the increased payments to
providers ($0.16 million). Because the federal govern-
ment matched 53% of MassHealth spending in 2003
[37], the net projected savings for the state government
would be approximately one million dollars.
Impact on Stakeholders
Although payments from the federal and state govern-
ment to providers would increase post policy, provid-
ers would incur a net ﬁnancial loss of approximately
$100,000 with a 10% decrease in prescription reﬁlls
(Table 4). This loss reﬂects the increased number of
acute exacerbations and the fact that the government’s
reimbursement rate does not fully cover the actual cost
of care. Net pharmacy revenues would decrease under
the postpolicy scenario (Table 5). Institution of higher
copayments would reduce drug utilization, thus
decreasing MassHealth’s asthma-related ICS payments
to pharmacies by $2.26 million per year. Increased
patient outlays ($0.28 million per year among asth-
matic MassHealth beneﬁciaries) would not offset these
losses.
Table 2 Projected health outcomes for adult asthmatic
MassHealth population (n = 17,500) for 1 year*
Policy scenario
Urgent-care
visits
ED
visits Hospitalizations
Prepolicy (50¢ copayment) 13,185 3,871 1,340
Postpolicy ($2.00 copayment)
5% nonadherence 13,419 3,937 1,362
10% nonadherence† 13,654 4,004 1,384
15% nonadherence 13,888 4,068 1,406
20% nonadherence 14,123 4,135 1,429
10% nonadherence, only
among mild patients‡
13,480 3,925 1,353
10% nonadherence, only
among moderate
patients‡
13,727 4,009 1,379
10% nonadherence, only
among severe patients‡
13,762 4,079 1,421
Incremental heath burden due to policy
5% nonadherence 234 66 22
10% nonadherence† 469 133 44
15% nonadherence 703 197 67
20% nonadherence 938 264 89
10% nonadherence, only
among mild patients‡
295 54 13
10% nonadherence, only
among moderate
patients‡
542 138 39
10% nonadherence, only
among severe patients‡
577 208 81
*Number of events expected in 1 year.
†Base-case assumption.
‡Assuming that nonadherence occurs only among a speciﬁc disease severity group,
whereas 100% adherence is assumed among the other severity groups.
ED, emergency department.
Table 3 Projected MassHealth payments for adult asthmatic
MassHealth population (n = 17,500) for 1 year*
Policy scenario
Payment ($) to: Total
payment ($)†Providers Pharmacy
Prepolicy (50¢ copayment) 12.05 19.75 31.80
Postpolicy ($2.00 copayment)
5% nonadherence 12.13 18.46 30.59
10% nonadherence‡ 12.21 17.49 29.70
15% nonadherence 12.30 16.51 28.81
20% nonadherence 12.38 15.54 27.92
10% nonadherence, only
among mild patients§
12.11 18.13 30.24
10% nonadherence, only
among moderate
patients§
12.21 18.13 30.34
10% nonadherence, only
among severe patients§
12.33 16.22 28.55
Incremental payment due to policy
5% nonadherence 0.08 -1.29 -1.21
10% nonadherence‡ 0.16 -2.26 -2.10
15% nonadherence 0.25 -3.24 -2.99
20% nonadherence 0.33 -4.21 -3.88
10% nonadherence, only
among mild patients§
0.06 -1.62 -1.56
10% nonadherence, only
among moderate
patients§
0.16 -1.62 -1.46
10% nonadherence, only
among severe patients§
0.28 -3.53 -3.25
*All costs are in millions of US dollars.
†53% of payment is borne by the federal government; 47% by the state.
‡Base-case assumption.
§Assuming that nonadherence occurs only among a speciﬁc disease severity group,
whereas 100% adherence is assumed among the other severity groups.
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Sensitivity Analysis
To examine the robustness of our ﬁndings, we con-
ducted one-way sensitivity analyses, varying each
factor through the range reported in the literature.
Tables 2–5 report the sensitivity of our results to the
prescription drug nonadherence rate. Increased drug
nonadherence and the consequent degradation of lung
function would result in increased acute-care utiliza-
tion (Table 2). MassHealth would expect further
savings with increased drug nonadherence, because
decreased drug payments to pharmacies would more
than offset higher acute-care payment to providers
(Table 3). This is a ﬁnding that persists with higher
copayments and reduced ICS consumption.
We also explored the possibility of 10% nonadher-
ence occurring only within a speciﬁc disease severity
group (Tables 2 and 3). In each instance, MassHealth
could expect to observe a net savings over a 1-year
time frame. Savings were greatest when nonadherence
occurred only among severe asthmatics, owing to the
high monthly drug cost in this subgroup. But even
among patients with mild asthma, low frequencies of
acute events resulted in net cost savings to the state.
Our results were sensitive to the AWP of ICS, but
less sensitive to changes in the assumed efﬁcacy of ICS,
the risk of acute events, acute-care costs, and the
payment-to-cost ratio for providers (Table 6). Our
results showed that regardless of assumptions, sensi-
tivity analyses were consistent with our base-case
analyses: MassHealth would expect savings, because
reduced payment to pharmacies would more than
offset increased outlays to providers. Even with 100%
prescription adherence under the postpolicy scenario,
MassHealth would still attain savings, because copay-
ments are automatically deducted from the reimburse-
ment to pharmacies [3].
Discussion
We employed a simulation model to project the policy
implications of a prescription drug copayment increase
on various stakeholders. Because inputs into simula-
tion models can be tailored on the basis of policy
makers’ speciﬁc interests, our approach could be espe-
cially helpful when estimating the impact of a particu-
lar variable on health and economic outcomes, or
Table 4 Projected revenues and losses for providers of adult asthmatic MassHealth population (n = 17,500) for 1 year*
Policy scenario
Government
reimbursement ($)
Provider
cost ($)
Projected
loss ($)
Prepolicy (50¢ copayment) 12.05 19.50 7.45
Postpolicy ($2.00 copayment)
5% nonadherence 12.13 19.63 7.50
10% nonadherence† 12.21 19.76 7.55
15% nonadherence 12.30 19.90 7.60
20% nonadherence 12.38 20.03 7.65
Incremental payment due to policy
5% nonadherence 0.08 0.13 0.05
10% nonadherence† 0.16 0.26 0.10
15% nonadherence 0.25 0.40 0.15
20% nonadherence 0.33 0.53 0.20
*All costs are in millions of US dollars.
†Base-case assumption.
Table 5 Projected revenues and losses for pharmacies for adult asthmatic MassHealth population (n = 17,500) for 1 year*
Policy scenario
MassHealth
reimbursement ($)
Patient
copayment ($)†
Total
revenue ($)
Prepolicy (50¢ copayment) 19.75 0.10 19.85
Postpolicy ($2.00 copayment)
5% nonadherence 18.46 0.40 18.86
10% nonadherence† 17.49 0.38 17.87
15% nonadherence 16.51 0.36 16.87
20% nonadherence 15.54 0.33 15.87
Incremental payment due to policy
5% nonadherence -1.29 0.30 -0.99
10% nonadherence‡ -2.26 0.28 -1.98
15% nonadherence -3.24 0.26 -2.98
20% nonadherence -4.21 0.23 -3.98
*All costs are in millions of US dollars.
†Values represent an upper bound because pharmacies do not collect 100% of copayments. Stuart and Zacker estimate that about 30% of pharmacies fail to collect copayment
with copayment increases [13].
‡Base-case assumption.
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when empirical data are not applicable to the precise
situation where the policymaker’s interest lies. We con-
ducted extensive sensitivity analyses to estimate the
impact of inﬂuential model parameters, and regardless
of assumptions, they were consistent with our base-
case analyses. Nevertheless, because simulation models
are based on assumptions and estimations from other
studies, our projections should be validated by an
empirical analysis.
Given the budget constraints and ﬁnancial pressures
facing Medicaid programs nationwide, there are sound
economic reasons to institute cost-containment poli-
cies to curb unnecessary utilization by forcing consum-
ers to internalize externalities associated with their
consumption of scarce sources. Nevertheless, our
analysis suggests that the current copayment policy
creates distinct winners and losers that may not reﬂect
public policy objectives being pursued. Using the
example of ICS therapy for asthmatic MassHealth
beneﬁciaries, we ﬁnd that an increase in prescription
drug copayment would shift the ﬁnancial burden from
MassHealth to other stakeholders. Asthmatic patients
would shoulder a heavier burden in the form of
increased out-of-pocket payment and additional acute
exacerbations. This ﬁnding persists over a broad range
of assumptions regarding drug nonadherence rates,
drug efﬁcacy, AWP of ICS, risk of acute event, and
acute-care cost. Our analysis only takes into account
direct out-of-pocket costs to the patient. Additional
acute exacerbations are also likely to impact quality-
of-life and incur indirect costs due to disability and lost
productivity.
Our ﬁndings are consistent with previous studies
[4,7,10,13,18], which suggest that cost-sharing poli-
cies have negative effects on health outcomes among
the poor and sick. It can be argued that our nonadher-
ence estimate of 10% is less conservative, considering
that the new copayment requirement was only $2.00
per prescription. Nevertheless, it represents a 300%
increase from the previous copayment, 50¢. Moreover,
chronic conditions, such as diabetes, metal illness, high
blood pressure, and asthma require multiple prescrip-
tions, even small copayments add up quickly for low-
income patients with chronic diseases [10]. Given the
high prevalence of chronic diseases among Medicaid
beneﬁciaries [10,13], health outcomes might deterio-
rate even further than in our base-case analysis, if
potential nonadherence to multiple medications was
considered.
Although our analysis suggests that providers
would receive additional payments from MassHealth,
this should not be interpreted to mean that higher drug
copayments represent a net ﬁnancial gain for provid-
ers. MassHealth reimbursement rates to providers are
reported to be lower than actual cost [36,40]; hence,
increased acute event caseloads in a postpolicy sce-
nario could pose ﬁnancial problems to providers.
MassHealth beneﬁciaries may encounter higher barri-
ers to care [21,41], because ﬁnancially stressed provid-
ers may refuse to participate in MassHealth programs.
We assumed that pharmacies would successfully
collect all copayments from patients. Nevertheless,
federal laws require that pharmacies dispense pre-
scribed medication regardless of Medicaid patients’
ability to pay the copayment [1,13]. If, as has been
reported, more Medicaid patients fail to make the
increased copayment, pharmacies may incur even
higher ﬁnancial loss with the copayment increase
[10,13].
There is reason to worry that increasing copayment
may not be the most effective mechanism available to
the state to control health-care spending. As we have
noted above, the federal government provides match-
ing funds that covers more than half the cost of Med-
icaid spending in Massachusetts. With the institution
of the copayment, more than half the savings that
accrue to the state also pass directly to the federal
government. Given the losses—both the ﬁnancial costs
and the adverse health effects—remain in state, there is
an inevitable net loss to the people of Massachusetts,
when viewed from a local societal perspective, which is
built into the structure of this policy.
Nationwide, approximately 6 million beneﬁciaries
dually eligible for Medicare and Medicaid transitions
Table 6 One-way sensitivity analyses for the asthmatic MassHealth population (n = 17,500) for 1 year*
Variable
Payment ($) to
Totalpayment ($)†Providers Pharmacy
Incremental payment due to policy
Base case 0.16 -2.26 -2.10
Drug efﬁcacy (biased toward ICS therapy) 0.25 -2.26 -2.01
Drug price (biased toward ICS therapy) 0.16 -1.27 -1.11
Acute-care events risk (biased toward ICS therapy) 0.26 -2.26 -2.00
Acute-care events risk (biased against ICS therapy) 0.12 -2.26 -2.14
Acute-care cost (biased toward ICS therapy) 0.49 -2.26 -1.77
Acute-care cost (biased against ICS therapy) 0.08 -2.26 -2.18
Cost-to-reimbursement ratio for providers (biased toward ICS therapy) 0.22 -2.26 -2.04
*All costs are in millions of US dollars.
†53% of payment is borne by the federal government; 47% by the state government.
ICS, inhaled corticosteroids.
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form Medicaid to Medicare Part D drug coverage in
2006 and will face higher copayments as a result.
Other low-income beneﬁciaries will also face copay-
ments of between $1 and $5 depending on their
income levels and the drug they are taking.
This study has several limitations. First, we assumed
that physicians’ prescribing behavior would not change
as a result of the copayment increase. If physicians
increased the average prescription size as a result of
increased copayment, then Medicaid beneﬁciaries
would make fewer copayments and their monthly
ﬁnancial burden per ICS payment would be smaller.
Currently, Medicaid programs in Massachusetts, New
York andCalifornia allowup to amaximumof 90 days’
supply of drugs to be dispensedwith one copayment [6].
Nevertheless, 40 other state Medicaid programs limit
the supply of medication dispensed on one prescription
to 30 to 34 days [6], therefore physicians could not
increase prescription size. Our assumption that physi-
cians’ prescribing behavior would not change is consis-
tent with a previous study [19].
Second, Medicaid patients are a ﬂuid group, and
more than one-third of Medicaid beneﬁciaries lose
coverage within 12 months [42]. This lack of continu-
ous enrollment led us to choose a 1-year time horizon.
Whether there would be a long-term deterrent effect of
a copayment increase on the ICS usage is not clear.
Third, drug rebates from manufacturers to the
federal and the state government were not included in
our analysis: the states and federal government share
in the rebates in proportion to their share of the cost of
the drugs [43]. The rebate is estimated based on the
Average Manufacturer Price (AMP), but AMP of ICS
was not publicly available. Including the drug rebate in
our analysis would reduce the size of the savings to
MassHealth.
Fourth, we did not incorporate a potential increase
in the utilization of short-acting beta-agonist resulting
from ICS nonadherence, because of the limited number
of available studies. In addition, we assumed that there
would be no effect on the utilization of rescue therapies
for patients experiencing acute exacerbations.
Finally, data on the impact of a copayment
increase on the asthmatic Medicaid beneﬁciaries are
limited. Many of the studies that report on price sen-
sitivity were old. Since these studies were conducted,
the volume of prescription drug use and polyphar-
macy for a number of conditions has increased and it
is not clear what impact these trends would have on
the price responsiveness among Medicaid enrollees.
We conducted sensitivity analyses to explore the
variations of noncompliance rates in our results, yet
our ﬁndings in this regard are speculative. Further-
more, our analysis is based on adult, asthmatic Med-
icaid beneﬁciaries; the results may not be applicable
to children or other patients with higher incomes and
better health status.
Conclusion
Using the example of ICS therapy in the asthmatic
MassHealth population, we ﬁnd that increasing copay-
ments for MassHealth beneﬁciaries would result in
greater numbers of acute events and shift the ﬁnancial
burden from MassHealth to pharmacies and Medicaid
beneﬁciaries in a 1-year time horizon. State Medicaid
programs should weigh whether short-term cost
savings—more than half of which will devolve to the
federal government—may be offset by the adverse eco-
nomic and health consequences shouldered by other
stakeholders over the longer term.
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